Additional Relevant Details DURECT Corporation today announced that its licensee, Pain Therapeutics has announced that an Advisory Committee of the U.S. Food and Drug Administration will review the REMOXY New Drug Application, in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016.